# APBA Kısa Özet
This multicenter, open-label randomized controlled trial evaluated the efficacy and safety of a fully self-administered, app-based biofeedback intervention for the prevention of episodic migraine. 279 adults (mean age 41 years; 92% women) were randomized to daily biofeedback via a mobile application (n=140) or waitlist control (n=139) for 12 weeks. The primary outcome was the change in monthly migraine days (MMDs) from baseline to weeks 9-12. Results demonstrated a statistically significant reduction of 0.9 days in MMDs in the intervention group compared to the control group (between-group difference, 0.9 days; 95% CI, 0.3 to 1.5; P = 0.002). Secondary outcomes included improvements in migraine-specific quality of life (MSQ v2.1), with a mean difference of 5.3 points (95% CI, 2.1 to 8.6; P = 0.001). Adverse events were mild and device-related, with a total of 9 events reported across the intervention group.
# Çalışma neyi araştırdı?
The study aimed to evaluate the efficacy and safety of a fully self-administered, app-based biofeedback intervention for the prevention of episodic migraine. Specifically, researchers sought to determine whether daily use of a mobile application delivering biofeedback—providing real-time feedback on physiological parameters such as respiratory rate, heart rate, and skin conductance—could reduce the frequency of migraine attacks and improve migraine-specific quality of life. The investigation also explored the intervention's safety profile and potential side effects in a real-world setting.
# Yöntem
This open-label, randomized, waitlist-controlled multicenter trial included adults with episodic migraine assigned to 12 weeks of daily biofeedback or a waitlist control. The study population consisted of 279 participants (mean [SD] age, 41 [10] years; 92% women) selected from 1113 screened individuals. The intervention group received daily biofeedback training via a mobile application, focusing on teaching patients to regulate physiological responses. The control group waited 12 weeks before receiving the intervention and continued standard care. The primary outcome was the change in monthly migraine days (MMDs) from baseline to weeks 9-12. Secondary outcomes included migraine intensity, acute medication use, and migraine-specific quality of life (MSQ v2.1). Statistical analyses were performed according to the intention-to-treat principle by a statistician masked to treatment assignment.
# Temel bulgular
- Aylık migren günleri (MMD): The intervention group demonstrated an average reduction of 0.9 days in MMDs (95% CI, -1.4 to -0.5) compared to no change in the control group (0.0 days, 95% CI, -0.5 to 0.4). The between-group difference was 0.9 days (95% CI, 0.3 to 1.5; P = 0.002).
- Migren‑spesifik yaşam kalitesi (MSQ v2.1): Participants receiving biofeedback showed a mean improvement of 5.3 points in MSQ v2.1 total scores (95% CI, 2.1 to 8.6; P = 0.001).
- Güvenlik: A total of 9 device-related adverse events were reported, all of mild severity and requiring no additional treatment.
- Diğer ikincil sonuçlar: No statistically significant differences were found in migraine intensity or acute medication use between groups.
# Bulgular ne anlama geliyor?
The findings suggest that app-based self-administered biofeedback can modestly but significantly reduce the frequency of migraine days in patients with episodic migraine. The improvement in migraine-specific quality of life indicates a meaningful benefit for patients' daily functioning. While the absolute reduction of 0.9 days per month may be clinically modest for some individuals, it represents a viable, non-pharmacological option for migraine prevention. The favorable safety profile, characterized by mild, device-related adverse events only, supports the tolerability of this digital intervention. However, the open-label design necessitates cautious interpretation of the results, as performance and detection bias cannot be entirely ruled out.
# Klinik önem
This trial provides evidence that app-based biofeedback is an effective and safe adjunctive option for the prevention of episodic migraine. It offers a digital, self-administered tool that can increase access to care, particularly for patients seeking non-pharmacological therapies. The ability to deliver treatment via a widely available mobile platform may improve adherence and reduce the burden on healthcare systems. However, clinicians should consider the study's limitations—including the predominantly female sample, the open-label design, and the relatively short 12-week follow-up—when counseling patients. Individual patient factors, such as migraine frequency, treatment history, and technology access, should guide shared decision-making.
# Sınırlılıklar
- Açık‑etiketli tasarım: The open-label nature of the study means that both participants and researchers were aware of the treatment assignment, which could introduce performance bias and detection bias despite the masked statistician for outcome analysis.
- Bekleme‑listesi kontrolü: The waitlist control group may have received concurrent treatments, placebo effects, or spontaneous improvement over the 12-week period, potentially attenuating the observed treatment effect.
- Cinsiyet dağılımı: 92% of participants were women, limiting the generalizability of the results to male populations and raising questions about potential sex-based differences in treatment response.
- Kısa takip süresi: The 12-week duration limits the ability to assess long-term efficacy, durability of effect, and long-term safety.
- Maskelenmiş istatistikçi: While the intention-to-treat analysis was performed by a masked statistician, the open-label design for participants and clinicians may still introduce biases that the masking of the statistician does not fully mitigate.
Overall, this study supports the potential of app-based biofeedback as a valuable tool in migraine management, but future research with longer follow-up, larger and more balanced gender cohorts, and blinded designs is needed to confirm and extend these findings.